ACD/Labs Introduces Andrew Anderson as Vice President of Business Development
News Dec 16, 2015
Anderson joins ACD/Labs from PepsiCo where he was responsible for technology scouting across a variety of research categories. In this role, Anderson spent four years identifying external technologies that deliver value in addressing company goals, and supported the successful in-licensing of technologies by helping to ensure successful implementations. Prior to joining PepsiCo, Anderson spent nearly 10 years in various sales, sales management, and strategic partnership roles at Symyx Technologies, ACD/Labs, as well as an analytical lab manager position at Pfizer.
"ACD/Labs has always been at the forefront of delivering solutions that help R&D organizations become more agile and productive,” said Anderson. “My goal in this new role is to empower our customers by continuing to develop solutions that accelerate scientific research and promote collaboration.”
“This is an exciting time for our company as we grow our informatics business to better address our customers’ evolving needs, and the timing could not be better for Andrew to rejoin the ACD/Labs team,” said Daria Thorp, CEO and President of ACD/Labs. “His expertise, combined with the relationships he has built over the years, will bring a global perspective and strategic approach to driving the growth of our business.”
An artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019